Nasa Rhinathiol (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasa Rhinathiol, is an alpha‑adrenergic agonist presented as a nasal spray for intranasal use. It relieves nasal congestion by reducing swelling of the nasal mucosa in adults and children when appropriate. GNH USA supplies Nasa Rhinathiol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a selective alpha‑1 adrenergic agonist used to relieve nasal congestion in various upper‑respiratory conditions. - Common cold: reduces nasal blockage and improves breathing. - Sinusitis: alleviates congestion of the nasal passages. - Allergic rhinitis: decreases swelling of the nasal mucosa and eases airflow.

Adverse reactions may occur with intranasal use of Xylometazoline Hydrochloride.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Headache. - Altered taste perception.

Serious or Rare Side Effects: - Severe hypertension. - Cardiac arrhythmia. - Nasal septum perforation. - Anaphylactic reaction. - Rebound congestion (rhinitis medicamentosa) after prolonged use.

Before using Nasa Rhinathiol, consider the following safety measures. - Use duration: limit treatment to 3‑5 days to avoid rebound congestion. - Age restrictions: not recommended for children under 6 years without medical supervision. - Pregnancy and lactation: consult a healthcare professional before use. - Cardiovascular disease: use with caution due to possible systemic vasoconstriction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride may interact with other medicines.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: increased risk of hypertensive crisis. - Other nasal decongestants: additive vasoconstriction may cause severe hypertension. - Sympathomimetic agents (e.g., pseudoephedrine): may potentiate cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible reduction in blood‑pressure‑lowering effect. - Beta‑blockers: may mask tachycardia signs. - Tricyclic antidepressants: potential additive sympathomimetic activity.